- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 239/69 - Benzènesulfonamido-pyrimidines
Détention brevets de la classe C07D 239/69
Brevets de cette classe: 85
Historique des publications depuis 10 ans
|
5
|
6
|
5
|
7
|
10
|
6
|
4
|
1
|
0
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Xenon Pharmaceuticals Inc. | 195 |
7 |
| Vertex Pharmaceuticals Incorporated | 1579 |
5 |
| ESSA Pharma Inc. | 34 |
5 |
| Eastern Virginia Medical School | 64 |
3 |
| The Regents of the University of California, Santa Cruz | 17 |
3 |
| Thomas Jefferson University | 555 |
3 |
| University of Dundee | 219 |
3 |
| ZaCh System S.p.A. | 22 |
3 |
| BASF SE | 21306 |
2 |
| Genentech, Inc. | 4114 |
2 |
| FUJIFILM Corporation | 30594 |
2 |
| ADAMA Agan Ltd. | 446 |
2 |
| Generics [UK] Limited | 106 |
2 |
| Genzyme Corporation | 1382 |
2 |
| Sanford-Burnham Medical Research Institute | 123 |
2 |
| The United States of America Department of Health | 2 |
2 |
| Novartis AG | 10173 |
1 |
| AstraZeneca AB | 2824 |
1 |
| AstraZeneca UK Limited | 523 |
1 |
| Massachusetts Institute of Technology | 10282 |
1 |
| Autres propriétaires | 33 |